Pfizer Stock Below $30: Is It Time to Buy?
Pfizer (NYSE:PFE) has struggled with several challenges over recent years, including declining revenue from its coronavirus business and patent expirations for key drugs like Eliquis. Despite these issues, the company's second-quarter results exceeded expectations, driven by strong performance in non-COVID products and newly launched or acquired therapies. Pfizer reported $15 billion in quarterly revenue, a 1% increase year-over-year that beat analyst forecasts. Adjusted earnings per share were slightly down but still ahead of estimates. The company's newer drugs contributed significantly to the growth, with non-COVID sales rising by 5%. Eliquis remains Pfizer’s top-selling product and is expected to face generic competition in the late decade. Looking forward, analysts believe that Pfizer has a strong pipeline with over 95 active programs, including promising new molecular entities. If successful, these could lead to multiple blockbuster drugs across oncology and weight-loss therapies. However, success will depend on clinical trial outcomes and market acceptance.
Tickers: $PFE